Market Access News | pharmaphorum

News

Market Access

Sanofi's Dupixent gets FDA nod for chronic hives indication

Dupixent's seventh indication is chronic hives, where a new treatment hasn't been approved since Novartis's Xolair in 2014

Market Access

New FDA head says no more pharma on advisory committees

The announcement signals a new administration attempting to distance itself from industry, but the actual impact seems small.

News

WHO (sans US) finishes draft pandemic preparedness agreement

The WHO has concluded negotiations on a 30-page draft agreement on pandemic preparedness. It goes before the assembly for consideration in May.

News

Tariffs spelled out with Scrabble letters

Tariffs 'could cancel out discounts with biosimilars'

Tariffs on US pharma imports could remove discounts offered to health systems by biosimilars and threaten the future of the sector, says a non-profit.

News

There's good news for RSV jab firms at delayed ACIP meeting

GSK and Pfizer could see a resurgence in sales of their RSV vaccines if new recommendations at a CDC expert meeting are confirmed by agency leaders.

News

FDA clears first migraine DTx from Click Therapeutics

Click Therapeutics' digital therapeutic (DTx) for migraine prevention has been cleared by the FDA, becoming the first treatment of its type in the US.

Sanofi's Dupixent gets FDA nod for chronic hives indication

New FDA head says no more pharma on advisory committees

WHO (sans US) finishes draft pandemic preparedness agreement

Tariffs 'could cancel out discounts with biosimilars'

There's good news for RSV jab firms at delayed ACIP meeting

FDA clears first migraine DTx from Click Therapeutics

Lilly UK recruits ex-England cricketer as obesity champion

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks